The BioPharm Brief: Priority Review, ADC Progress, and New Frontiers in Fibrosis

Jun 30, 06:49 PM
Headliner
Share
Subscribe

From a potential first at home treatment for thyroid eye disease to progress in lymphoma and a first in class antibody entering the clinic for kidney fibrosis, today's BioPharm Brief highlights three developments advancing biologic drug development.

Share
Subscribe
Next
The BioPharm Brief: Alzheimer's Advances, Bispecific Innovation, and a New TED Therapy
Top episodes
The BioPharm Brief: Early Design Risks, Oncology Signals, and a Biosimilars Power Move
by The BioPharm Brief
The BioPharm Brief: Regulatory Shifts, Rare Disease Innovation, and Precision Drug Development Trends
by The BioPharm Brief
The BioPharm Brief: What’s the Big Deal About Multispecific T-Cell Engagers in Cancer and Autoimmune Diseases?
by The BioPharm Brief